A refrigerant agent and its preparation method and application in the refrigeration process of Chinese medicine oral liquid

Abstract

The present application relates to the technical field of cold storage technology, and specifically discloses a refrigerant agent and its preparation method and its application in the cold storage process of Chinese medicine oral liquid. The refrigerant agent disclosed in the present application is composed of the following components: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-1.0 parts of corrosion inhibitor additives, 0.4-1.0 parts of scale inhibitor additives, and 0.5-1.5 parts of compatibilizer; the scale inhibitor additive is composed of sodium phosphite and polyacrylic acid in a weight ratio of 1-5:1-5; the compatibilizer is composed of 20-30wt% lauryl dimethylamine oxide aqueous solution and 5-10wt% zinc lactate aqueous solution in a weight ratio of 9:1-7. The refrigerant agent obtained in the present application has excellent corrosion resistance. The above-mentioned refrigerant agent is used to refrigerate the antiviral oral liquid, and the cooling process can be accurately controlled, so that the temperature of the liquid is more uniform, the difference between finished batches is reduced, and the product stability is improved.

Description

Technical Field

[0001] The present application relates to the technical field of cold storage technology, and specifically to a refrigerant agent and a preparation method thereof and an application thereof in the cold storage technology of a traditional Chinese medicine oral liquid. Background Art

[0002] Refrigerant, also known as refrigerant, is a substance that circulates in the refrigeration system and absorbs and releases heat through phase change (mutual conversion between gas and liquid) to achieve the cooling effect. Refrigerant is widely used in refrigeration equipment such as household air conditioners, refrigerators, cold storage, and car air conditioners.

[0003] When choosing a refrigerant, you need to consider factors such as chemical stability, thermal properties, environmental friendliness, and cost. Traditional refrigerants such as Freon have been gradually phased out due to their destructive effects on the ozone layer. Calcium chloride refrigerants are highly corrosive, causing material damage and refrigerant leakage; some refrigerants are highly scaling, which can easily cause pipe blockage and reduced heat transfer efficiency; these traditional refrigerants have greatly increased production costs and affected the quality of enterprise operations.

[0004] In summary, a new type of refrigerant agent needs to be provided. Summary of the invention

[0005] In order to solve the above technical problems, the present application provides a refrigerant agent and a preparation method thereof and an application thereof in the refrigeration process of a Chinese medicine oral liquid.

[0006] The present application provides a refrigerant agent, which is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-1.0 parts of corrosion inhibitor additives, 0.4-1.0 parts of scale inhibitor additives, and 0.5-1.5 parts of compatibilizer; the scale inhibitor additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1-5:1-5;

[0007] The compatibilizer is composed of a mixture of 20-30 wt % lauryl dimethyl amine oxide aqueous solution and 5-10 wt % zinc lactate aqueous solution in a weight ratio of 9:1-7.

[0008] The present application utilizes the above-mentioned technical scheme to prepare a refrigerant agent, wherein sodium phosphite and polyacrylic acid have good compounding properties, and the composed scale inhibitor additive has the structural characteristics of phosphonic acid and carboxylic acid, which effectively improves the scale inhibition and corrosion inhibition properties of the refrigerant agent, and can be compounded with corrosion inhibitor additives that also have corrosion inhibition properties to achieve better scale inhibition and corrosion inhibition properties. The scale inhibition and corrosion inhibition properties are better than those of commonly used organic phosphonic acids, and the refrigerant agent is resistant to chlorine oxidation, high temperature, acid and alkali, and is more suitable for compounding with ethylene glycol, diethylene glycol, and triethanolamine to achieve better scale inhibition and corrosion inhibition effects. The refrigerant agent prepared in the present application is added to circulating cooling water to prevent scaling of calcium, magnesium and other ions in the circulating water and slow down the corrosion of water to equipment.

[0009] The present application uses a 20-30wt% lauryl dimethylamine oxide aqueous solution and a 5-10wt% zinc lactate aqueous solution in a weight ratio of 9:1-7 to form a compatibilizer. This is based on the consideration of the refrigerant composition, so that the various raw material components form a good composite performance, and the electrochemical compatibility with the commonly used metals (such as copper, aluminum, steel, etc.) in the refrigeration system is conducive to the refrigerant forming a stable passivation layer on the metal surface or having lower electrochemical corrosion. Adding an appropriate amount of corrosion inhibitor to the refrigerant forms a protective film on the metal surface, thereby isolating the refrigerant from direct contact with the metal, which can effectively slow down its corrosion rate on the equipment.

[0010] Preferably, the refrigerant is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-0.6 parts of corrosion inhibitor additives, 0.7-1.0 parts of scale inhibitor additives, and 0.5-1.5 parts of compatibilizer.

[0011] Preferably, the refrigerant is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-0.6 parts of corrosion inhibitor additives, 0.7-1.0 parts of scale inhibitor additives, and 0.8-1.2 parts of compatibilizer.

[0012] Preferably, the antiscaling additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1-3:3-5.

[0013] Preferably, the antiscaling additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1-2:4-5.

[0014] Through experimental analysis, it can be known that the scale inhibitor additive composed of sodium phosphite and polyacrylic acid mixed in the above weight ratio can effectively improve the corrosion resistance of the refrigerant agent.

[0015] Preferably, the compatibilizer is composed of a mixture of 20-30 wt % lauryl dimethyl amine oxide aqueous solution and 5-10 wt % zinc lactate aqueous solution in a weight ratio of 9:2-5.

[0016] Preferably, the compatibilizer is composed of a mixture of 23-28 wt % lauryl dimethyl amine oxide aqueous solution and 7-9 wt % zinc lactate aqueous solution in a weight ratio of 9:2-5.

[0017] Through experimental analysis, it can be known that the present application utilizes the above-mentioned weight ratio of lauryl dimethylamine oxide aqueous solution and zinc lactate aqueous solution to mix and form a compatibilizer, which can effectively improve the corrosion resistance of the refrigerant agent.

[0018] Preferably, the corrosion inhibitor additive is selected from one or more of benzotriazole, 2-mercaptobenzothiazole, dithizone, and 8-hydroxyquinoline.

[0019] In a second aspect, the present application provides a method for preparing the above-mentioned refrigerant agent, which specifically comprises the following steps:

[0020] Stir at room temperature, first stir and mix ethylene glycol and diethylene glycol evenly, then add corrosion inhibitor additives, scale inhibitor additives, and compatibilizer components in sequence, with an interval of 5 minutes. After all are added, stir for 20-30 minutes, and finally add triethanolamine to mix evenly to obtain the refrigerant agent.

[0021] In a third aspect, the present application provides a refrigeration process for oral Chinese medicine liquid, which specifically includes the following steps: using a storage tank with a jacket for cooling and refrigeration, introducing the above-mentioned refrigerant into the jacket, and cooperating with an intelligent control system on the storage tank to accurately control the cooling process of the intermediate product;

[0022] A temperature sensor is installed in the tank body of the storage tank, and the temperature sensor is automatically linked to the stirring facility in the tank through an intelligent control system. According to the temperature monitoring results, the temperature difference at various locations in the tank body is judged, and the stirring speed of the agitator is adjusted according to the degree of temperature difference, thereby realizing the automatic adjustment function of temperature and stirring speed. When the intermediate product as a whole reaches the refrigeration temperature required by the process, the stirring automatically stops to ensure that the product temperature is uniform during the cooling process.

[0023] In summary, the technical solution of this application has the following effects:

[0024] The present application utilizes sodium phosphite and polyacrylic acid in a specific weight ratio to form a scale inhibitor, and utilizes a specific weight ratio of 20-30wt% lauryl dimethylamine oxide aqueous solution and 5-10wt% zinc lactate aqueous solution to form a compatibilizer, which has good compounding performance with the remaining ingredients and is more suitable for compounding with ethylene glycol, diethylene glycol, and triethanolamine to achieve better scale inhibition and corrosion inhibition effects, and slow down the corrosion of water to equipment.

[0025] By using the refrigerant provided in the present application to refrigerate the antiviral oral liquid, the cooling process can be accurately controlled, making the temperature of the liquid more uniform during the cooling process, reducing the batch differences of the finished antiviral oral liquid and improving the product stability. DETAILED DESCRIPTION

[0026] Polyacrylic acid (CAS No.: 9003-01-4, Product No.: P104272) and polyaspartic acid (CAS No.: 25608-40-6, Product No.: P303238) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; the remaining reagents can be obtained commercially.

[0027] The present application is further described in detail below in conjunction with examples, comparative examples and performance testing experiments. These examples should not be construed as limiting the scope of protection claimed in the present application.

[0028] Example

[0029] Examples 1-7

[0030] Embodiments 1-7 each provide a refrigerant agent.

[0031] The difference between the refrigerants in the above embodiments is that the amounts of the various raw material components are different, as shown in Table 1.

[0032] The specific preparation method of the refrigerant agent in the above embodiment is as follows.

[0033] Scale inhibitor additive: It is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1:4.

[0034] Compatibilizer: A mixture of 25 wt% lauryl dimethylamine oxide aqueous solution and 8 wt% zinc lactate aqueous solution in a weight ratio of 9:3.

[0035] According to the amount of each raw material shown in Table 1, weigh the corresponding weight of the raw material components respectively; stir at room temperature, first stir and mix ethylene glycol and diethylene glycol evenly, and then add the corrosion inhibitor additive, scale inhibitor additive, and compatibilizer components in sequence, with an interval of 5 minutes. After all are added, stir for another 25 minutes, and finally add triethanolamine to mix evenly to obtain the refrigerant agent.

[0036] Table 1 Amount of each raw material component in Examples 1-7 and Comparative Examples 1-3

[0037]

[0038]

[0039] Embodiment 8-10

[0040] Embodiments 8-10 each provide a refrigerant agent.

[0041] The difference between the refrigerant agent in the above embodiment and that in embodiment 2 is the type of anti-scaling additive, as shown below.

[0042] In Example 8: the scale inhibitor additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 5:1.

[0043] In Example 9: the scale inhibitor additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 3:5.

[0044] In Example 10: the scale inhibitor additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 2:5.

[0045] The remaining raw material components of the refrigerant agent in the above embodiment and embodiment 2, the amount of each raw material component and the preparation method of the refrigerant agent are the same.

[0046] Examples 11-16

[0047] Embodiments 11-16 each provide a refrigerant agent.

[0048] The difference between the refrigerant agent in the above embodiment and embodiment 2 is the type of compatibilizer, which is specifically shown as follows.

[0049] In Example 11: the compatibilizer is composed of a mixture of 25 wt % lauryl dimethyl amine oxide aqueous solution and 8 wt % zinc lactate aqueous solution in a weight ratio of 9:1.

[0050] In Example 12: the compatibilizer is composed of a mixture of 25 wt % lauryl dimethyl amine oxide aqueous solution and 8 wt % zinc lactate aqueous solution in a weight ratio of 9:7.

[0051] In Example 13: the compatibilizer is composed of a mixture of 20 wt % lauryl dimethylamine oxide aqueous solution and 8 wt % zinc lactate aqueous solution in a weight ratio of 9:1.

[0052] In Example 14: the compatibilizer is composed of a mixture of 30 wt % lauryl dimethylamine oxide aqueous solution and 8 wt % zinc lactate aqueous solution in a weight ratio of 9:1.

[0053] In Example 15: the compatibilizer is composed of a mixture of 25 wt % lauryl dimethyl amine oxide aqueous solution and 5 wt % zinc lactate aqueous solution in a weight ratio of 9:1.

[0054] In Example 16: the compatibilizer is composed of a mixture of 25 wt % lauryl dimethylamine oxide aqueous solution and 10 wt % zinc lactate aqueous solution in a weight ratio of 9:1.

[0055] The remaining raw material components of the refrigerant agent in the above embodiment and embodiment 2, the amount of each raw material component and the preparation method of the refrigerant agent are the same.

[0056] Comparative Example

[0057] Comparative Examples 1-3

[0058] Comparative Examples 1-3 each provide a refrigerant agent.

[0059] The difference between the refrigerant in the comparative example and that in Example 2 is that the amounts of the raw material components are different, as shown in Table 1.

[0060] The remaining raw material components of the refrigerant agent in the comparative example and Example 2, the amounts of the raw material components, and the preparation method of the refrigerant agent are the same.

[0061] Comparative Example 4

[0062] Comparative Example 4 provides a refrigerant agent.

[0063] The difference between the refrigerant agent in this comparative example and that in Example 2 is that the anti-scaling additive is composed of a mixture of sodium pyrophosphate and polyacrylic acid in a weight ratio of 1:4.

[0064] The remaining raw material components of the refrigerant agent in this comparative example and Example 2, the amounts of each raw material component, and the preparation method of the refrigerant agent are the same.

[0065] Comparative Example 5

[0066] Comparative Example 5 provides a refrigerant agent.

[0067] The difference between the refrigerant agent in this comparative example and that in Example 2 is that the anti-scaling additive is composed of a mixture of sodium phosphite and polyaspartic acid in a weight ratio of 1:4.

[0068] The remaining raw material components of the refrigerant agent in this comparative example and Example 2, the amounts of each raw material component, and the preparation method of the refrigerant agent are the same.

[0069] Comparative Example 6

[0070] Comparative Example 6 provides a refrigerant agent.

[0071] The difference between the refrigerant agent in this comparative example and that in Example 2 is that the compatibilizer is composed of a mixture of 25 wt % sodium dodecylbenzene sulfonate aqueous solution and 8 wt % zinc borate aqueous solution in a weight ratio of 9:4.

[0072] The remaining raw material components of the refrigerant agent in this comparative example and Example 2, the amounts of each raw material component, and the preparation method of the refrigerant agent are the same.

[0073] Comparative Example 7

[0074] Comparative Example 7 provides a refrigerant agent.

[0075] The difference between the refrigerant agent in this comparative example and that in Example 2 is that the compatibilizer is composed of a mixture of 18 wt % lauryl dimethyl amine oxide aqueous solution and 12 wt % zinc lactate aqueous solution in a weight ratio of 9:8.

[0076] The remaining raw material components of the refrigerant agent in this comparative example and Example 2, the amounts of each raw material component, and the preparation method of the refrigerant agent are the same.

[0077] Performance testing

[0078] Corrosion inhibition performance test: The static coupon weight loss method was used to evaluate the corrosion of different refrigerants (20wt% refrigerant during the test) to Q235 steel, aluminum alloy, copper alloy, and rubber test pieces. The test time was 1130 hours and the test temperature was 50°C.

[0079] Performance test results: as shown in Table 2.

[0080] Table 2 Performance test results of refrigerant agents in Examples 1-16 and Comparative Examples 1-7

[0081]

[0082] Combined with Table 2, by comparing the performance test results of the refrigerant agent in Examples 1-16 and Comparative Examples 1-7, it can be seen that the refrigerant agent obtained by using the technical solution of the present application has excellent corrosion resistance.

[0083] By comparing the test results of Examples 1-5, it can be seen that the present application controls the dosage of corrosion inhibitor additives to 0.4-0.6 parts and the dosage of scale inhibitor additives to 0.7-1.0 parts, which can further improve the corrosion resistance of copper alloy and rubber test pieces during the application of refrigerant agents.

[0084] By comparing the test results of Examples 2, 6-7, it can be seen that the application controls the amount of compatibilizer to 0.8-1.2 parts, which can further improve the corrosion resistance of Q235 steel and copper alloy during the application of the refrigerant agent.

[0085] By comparing the test results of Examples 2, 8-10, it can be seen that the present application utilizes a scale inhibitor composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1-3:3-5 to further improve the corrosion resistance of Q235 steel and aluminum alloy during the application of the refrigerant agent.

[0086] By comparing the test results of Examples 2 and 11-16, it can be seen that when a compatibilizer is composed of a mixture of 20-30wt% lauryl dimethylamine oxide aqueous solution and 5-10wt% zinc lactate aqueous solution in a weight ratio of 9:2-5, the corrosion resistance of the refrigerant agent in the application process can be further broadened.

[0087] Application Example 1-16

[0088] The specific preparation process of the antiviral oral liquid in this application example is as follows:

[0089] (1) Weigh 128.57 g of Radix Isatidis, 57.14 g of Gypsum, 60.71 g of Rhizoma Phragmites, 32.14 g of Radix Rehmanniae, 25 g of Radix Curcumae, 25 g of Rhizoma Anemarrhenae, 25 g of Rhizoma Acorus Calamus, 28.57 g of Pogostemon Cablin, and 46.43 g of Fructus Forsythiae respectively, add appropriate amount of water, and boil for 3 hours. Collect volatile oil through oil-water separator to obtain 3.5 ml of volatile oil and 285 ml of aromatic water. Add appropriate amount of water to the residue and boil for 1 hour and 20 minutes. Filter and collect the filtrate. Combine the filtrates and discard the residue.

[0090] (2) The combined filtrate is concentrated in vacuo at a temperature below 65°C to a relative density of 1.12 (thermal measurement), cooled to room temperature, and 85% ethanol is slowly added while stirring to a concentration of 70±2% ethanol. The mixture is allowed to stand for 24 hours, filtered, and the supernatant is taken to recover ethanol and concentrated to a relative density of 1.09 (thermal measurement) to obtain a concentrated solution for later use.

[0091] (3) Take 15 g of hydroxypropyl-β-cyclodextrin and prepare a saturated aqueous solution. Add 2 ml of volatile oil dehydrated with anhydrous sodium sulfate. Control the temperature at 40-60° C. and stir for 5 hours at a stirring speed of 300 r / min to obtain a hydroxypropyl-β-cyclodextrin inclusion solution.

[0092] (4) At a temperature of 65°C, 300 ml of the antiviral concentrate was filtered, and 100 g of honey, 125 g of sucrose, and 12.5 g of hydroxypropyl-β-cyclodextrin inclusion complex were added. The pH of the mixed solution was 3.5. The solution was then cooled to 25°C, and the pH of the solution was adjusted to 4.5-5.5 using 6 mol / L sodium hydroxide solution. The solution was filtered until clear, and water was added to make the volume to 1000 ml. The fixed volume solution was filtered and sterilized to obtain an antiviral oral solution with a forsythin content of 85.63 μg / mL.

[0093] (5) Refrigeration of antiviral oral liquid: A storage tank with a jacket is used for cooling and refrigeration. The refrigerant prepared in the embodiment is introduced into the jacket. The cooling process of the intermediate product can be accurately controlled by cooperating with the intelligent control system on the storage tank. A temperature sensor is installed in the tank body, and the temperature sensor is automatically associated with the stirring facility in the tank through the intelligent control system. According to the temperature monitoring results, the temperature difference at various places in the tank body is judged, and the stirring speed of the stirrer is adjusted according to the degree of temperature difference, so as to realize the automatic adjustment function of temperature and stirring speed. When the intermediate product as a whole reaches the refrigeration temperature required by the process, the stirring automatically stops to ensure that the product temperature is uniform during the cooling process.

[0094] In the process of cooling the temperature of the intermediate product of the antiviral oral liquid from an initial temperature of 25°C to 15°C, the cooling rate is controlled at 0.5-1.0°C / min, and when it drops to 15°C (to test the temperature uniformity of the drug solution), it is kept warm for at least 30 minutes; in the process of cooling from 15°C to 10°C, the cooling rate is controlled at 0.4-0.8°C / min, and when it drops to 10°C, it is kept warm for at least 30 minutes; in the process of cooling from 10°C to 8°C, the cooling rate is controlled at 0.1-0.4°C / min, and when it drops to 8°C (to test the temperature uniformity of the drug solution), it is kept warm for at least 60 minutes; when the temperature is below 8°C, the cooling rate does not exceed 0.2°C / min, until it drops to the predetermined refrigerated temperature of 2°C and is stored for 48 hours. Subsequent operations are carried out according to the preparation process flow to finally obtain the antiviral oral liquid product.

[0095] During the application process, we focused on three aspects: precise control of the cooling process, uniform temperature during the cooling process, and small temperature fluctuations during the static process, which reduced the batch differences of the antiviral oral liquid and improved the product stability. The forsythiaside content of the product decreased very little after refrigeration, and the clarity of the liquid was maintained, with no obvious precipitation.

[0096] Performance testing

[0097] (1) Uniformity of cooling of liquid medicine temperature: Place a temperature sensor near the highest, middle, and lowest parts of the liquid medicine tank to test the liquid medicine temperature at different locations when the temperature drops to 15°C and 8°C.

[0098] (2) Stability test method of antiviral oral liquid: The antiviral oral liquid samples were placed in a constant temperature and humidity chamber at 40±2°C and 75±5% relative humidity. The pH and forsythiaside content of the antiviral oral liquid were tested at 0, 3, and 6 months.

[0099] The specific method for detecting the content of Forsythiaside is as follows: refer to the Forsythiaside quality detection standard in Part 1 of the 2020 edition of the "Chinese Pharmacopoeia", use the HPLC detection method, use octadecylsilane bonded silica gel as the filler; use acetonitrile-water solution with a volume ratio of 25:75 as the mobile phase; and the detection wavelength is 277nm.

[0100] Performance test results: as shown in Table 3.

[0101] Table 3 Application performance test results of refrigerant in application examples 1-16

[0102]

[0103]

[0104] Combined with the test results in Table 3, the use of the refrigerant provided in the present application to refrigerate the intermediate product of the antiviral oral liquid can accurately control the cooling process, making the temperature of the liquid medicine more uniform during the cooling process, reducing the batch differences of the finished antiviral oral liquid and improving the product stability.

[0105] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A refrigerant agent, characterized in that: The invention is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-1.0 parts of corrosion inhibitor additive, 0.4-1.0 parts of scale inhibitor additive, and 0.5-1.5 parts of compatibilizer; The anti-scaling additive is composed of a mixture of sodium phosphite and polyacrylic acid in a weight ratio of 1-5:1-5; The compatibilizer is composed of a mixture of 20-30wt% lauryl dimethylamine oxide aqueous solution and 5-10wt% zinc lactate aqueous solution in a weight ratio of 9:1-7; The corrosion inhibitor additive is selected from one or more of benzotriazole, 2-mercaptobenzothiazole, dithizone, and 8-hydroxyquinoline.

2. The refrigerant according to claim 1, characterized in that: The refrigerant agent is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-0.6 parts of corrosion inhibitor additives, 0.7-1.0 parts of scale inhibitor additives, and 0.5-1.5 parts of compatibilizer.

3. The refrigerant according to claim 1, characterized in that: The refrigerant agent is composed of the following components in parts by weight: 5-8 parts of ethylene glycol, 12-16 parts of diethylene glycol, 2-5 parts of triethanolamine, 0.4-0.6 parts of corrosion inhibitor additives, 0.7-1.0 parts of scale inhibitor additives, and 0.8-1.2 parts of compatibilizer.

4. The refrigerant according to claim 1, characterized in that: The anti-scaling additive is composed of sodium phosphite and polyacrylic acid in a weight ratio of 1-3:3-5.

5. The refrigerant according to claim 4, characterized in that: The anti-scaling additive is composed of sodium phosphite and polyacrylic acid in a weight ratio of 1-2:4-5.

6. The refrigerant according to claim 1, characterized in that: The compatibilizer is composed of a mixture of 20-30 wt % lauryl dimethyl amine oxide aqueous solution and 5-10 wt % zinc lactate aqueous solution in a weight ratio of 9:2-5.

7. The refrigerant according to claim 6, characterized in that: The compatibilizer is composed of a mixture of 23-28 wt % lauryl dimethyl amine oxide aqueous solution and 7-9 wt % zinc lactate aqueous solution in a weight ratio of 9:2-5.

8. The method for preparing the refrigerant agent according to any one of claims 1 to 7, characterized in that: The specific steps include: Stir at room temperature, first stir and mix ethylene glycol and diethylene glycol evenly, then add corrosion inhibitor additives, scale inhibitor additives, and compatibilizer components in sequence, with an interval of 5 minutes. After all are added, stir for 20-30 minutes, and finally add triethanolamine to mix evenly to obtain the refrigerant agent.

9. A cold storage process for Chinese medicine oral liquid, characterized in that: The use of the refrigerant agent described in any one of claims 1 to 7 specifically includes the following steps: using a storage tank with a jacket for cooling and refrigeration, passing the refrigerant agent into the jacket, and cooperating with the intelligent control system on the storage tank to accurately control the cooling process of the intermediate product.

Images